CD8A and neoplasm: Tumor vasculature‐targeted AFR therapy synergized strikingly with either mouse CD8‐AFN immunotherapy, human CAR T‐cell immunotherapy, or tumor vasculature‐targeted AFN‐II therapy, leading to complete eradication of large established tumors in mice without toxicity.